Short Seller Report Alleges ADMA Biologics Financial Misrepresentation

Culper Research released a short report accusing ADMA Biologics of misreporting, and ADMA denies the claims while reviewing the allegations; the short report is pressuring the stock. ADMA reported adjusted EPS of $0.21 (vs $0.18 consensus) and revenue of $139.16M (vs $139.40M consensus), and guided fiscal 2026 revenue >$635M (consensus $633.75M) and fiscal 2027 sales >$775M (consensus $771.8M). Shares were down 13.15% to $9.84 at publication, trading 28.2% below the 20-day SMA, 35.4% below the 100-day SMA, and down 45.7% over the past 12 months; RSI is 23.87 (oversold) and MACD is -0.7757 (below signal). Key technical levels: resistance $15, support $10.90.

Analysis

The short-seller report has turned what was an execution/visibility problem into a credibility event, which typically compresses trading multiples for small-cap therapeutics by 20–40% as investors price in forensic/legal risk and higher cost of capital. That derating is amplified for ADMA because its business relies on long-term supply contracts and white‑label relationships where counterparties react to perceived counterparty risk by tightening payment terms or adding audits — a gradual revenue impact that can play out over 3–12 months even if the allegations are ultimately disproven.

Technically and positioning-wise, the stock is in a classic capitulation setup: extreme momentum deterioration and very low RSI increase the probability of sharp intraday rallies driven by short-covering, especially around any independent audit announcement or SEC comment; however, any such rally is likely to fade without tangible remediation given the underlying trust issue. The appropriate time horizons therefore bifurcate: days for trading volatility and options gamma trades; quarters for whether guidance holds and customers/insurers stick; and 6–18 months for resolution of regulatory/legal outcomes and capital structure dilution risk.

Secondary winners are larger, diversified plasma/IG players and distributors that can pick up share or renegotiate pricing (GRFS, CSL, TAK), while service providers (third‑party auditors, legal advisors) see increased engagements — creating asymmetric information flows that favor larger peers with clean balance sheets. The clearest tail risk is regulatory or forensic findings that force restatements or covenant breaches which could push valuation to zero-recovery scenarios; conversely, a swift, credible third-party audit within 60–120 days is the single fastest pathway to materially recoup market cap losses.

Key Decisions for Investors

• Event-driven short (ADMA): Initiate a tactical short at current levels (~$10), size 2–4% portfolio, target $6 in 1–3 months (30–40% downside) with a hard stop-loss at $15 (limit loss ~50%). Rationale: exploit credibility shock and stretched technicals; cover or trim into any audit-positive prints or sustained institutional buybacks.
• Put-buy volatility play (ADMA options): Buy Jul-2026 $8 puts to capture tail risk with limited capital at risk; aim 3–5x payoff if report triggers regulatory action or revenue erosion over 6–12 months. Position size 1–2% given option theta and wide spreads.
• Pair trade to isolate company risk: Short ADMA equity and go long Grifols ADR (GRFS) equal dollar exposure, timeframe 3–12 months. This hedges sector/regulatory beta while capitalizing on market rotation from small-cap plasma risk to larger incumbents; expect 10–20% relative outperformance if ADMA derates further.
• Contrarian event long (conditional): Allocate a small, staged long (2% max) only after a clean independent audit or explicit SEC closure — initial buy at 15–25% of target position and add on confirmation of customer contract renewals. Reward: if credibility restored and guidance intact, stock can re-rate quickly; risk management via stop under new support and monitoring for dilution signals.